Investors should monitor upcoming data presentations at the MDA Conference (March 8–11, 2026) and the Q2 2026 BLA submission for z-rostudirsen as key catalysts. The strong cash runway reduces near-term dilution risk despite high burn.
Price Chart
Executive Summary
Dyne Therapeutics reported positive topline results from the Phase 1/2 DELIVER trial of z-rostudirsen in Duchenne muscular dystrophy, showing statistically significant dystrophin expression and functional improvements. The company plans a Q2 2026 BLA submission for accelerated approval, with a potential U.S. launch in Q1 2027. Cash remains strong at $1.1 billion, supporting operations into Q1 2028, despite increased R&D and net losses.
Key Financial Metrics
Key Facts
- Positive topline results from DELIVER trial: 5.46% normal dystrophin expression at 6 months (7-fold increase, p<0.0001); functional improvements in TTR and 10MWR vs. placebo (nominal p<0.05).
- Z-rostudirsen safety profile remains favorable, with mostly mild-to-moderate treatment-related adverse events.
- BLA submission for z-rostudirsen planned for Q2 2026; potential U.S. launch in Q1 2027 assuming Priority Review.
- Enrollment in ACHIEVE trial for z-basivarsen in DM1 on track for completion in Q2 2026, with BLA submission expected in early Q3 2027.
- Cash, cash equivalents, and marketable securities totaled $1.11 billion as of December 31, 2025, sufficient to fund operations into Q1 2028.
- R&D expenses increased to $398.3 million in 2025 from $281.4 million in 2024; net loss widened to $446.2 million in 2025 from $317.4 million in 2024.
Financial Impact
Increased R&D spend of $116.9 million YoY and net loss expansion of $128.8 million reflect advancing clinical programs, offset by strong cash position of $1.11 billion.
Risk Factors
- Clinical trial results are not powered for statistical significance on functional endpoints; confirmatory Phase 3 trials are required.
- Regulatory approval is not guaranteed, even with accelerated pathway plans.
- Increased operating losses may pressure valuation if clinical milestones are delayed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247269 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 17, 2026 6w ago | Insider Cluster | $26.15 $17.90 | ▲ +31.55% | ▲ +29.57% | $15.20 (+41.87%) |
Aug 14, 2026 6w ago | 144 | $26.15 $18.52 | ▼ −29.18% | ▼ −27.65% | $15.20 (−41.87%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▲ +27.94% | ▲ +25.95% | $15.20 (+40.86%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▼ −27.94% | ▼ −25.95% | $15.20 (−40.86%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▼ −27.94% | ▼ −25.95% | $15.20 (−40.86%) |
Jul 29, 2026 9w ago | Press Release | $25.73 $26.09 | ▲ +1.40% | ▼ −2.57% | $15.20 (−40.92%) |
Jul 22, 2026 10w ago | Press Release | $23.21 $26.78 | ▼ −15.38% | ▼ −12.48% | $15.20 (+34.51%) |
Jul 20, 2026 10w ago | 8-K | $23.45 $26.15 | ▲ +11.51% | ▲ +7.39% | $15.20 (−35.18%) |
Jun 30, 2026 13w ago | Insider Cluster | $21.79 $25.10 | ▲ +15.19% | ▲ +17.38% | $15.20 (−30.24%) |
Jun 29, 2026 13w ago | 144 | $22.21 $25.63 | ▼ −15.40% | ▼ −16.43% | $15.20 (+31.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access